IMNM

Rating neutralAI MemoPost-earnings T+3

Immunome

As of 2026-08-24/Post-earnings T+3/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

Varegacestat regulatory review toward PDUFA decision • 2027-04-28

Base target: $31 / p=45% prob

Biggest risk

The company remains loss-making and pre-commercial, with a $73.1 million quarterly net loss and $59.9 million of quarterly R&D expense. Approval, labeling, safety, enrollment, and commercial execution remain unresolved, while early-stage pipeline data may not translate into durable value. Recent open-market insider sales add a secondary sentiment overhang but are not operating evidence. [#SEC-8K-2026-08-11] [#SEC-FORM4-2026-08-12]

Invalidation

Break below $20 or thesis failure.

What would change my mind?

RINGSIDE produced statistically significant primary and key secondary endpoint results, varegacestat has entered FDA review with a defined PDUFA date, and $520.0 million of cash, cash equivalents, and marketable securities is expected to fund operations into 2028. Multiple additional oncology programs provide further milestone optionality. [#SEC-8K-2026-08-11]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-24

Base target

$31

p=45%

Bull target

$45

p=25%

Bear target

$20

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings pipeline execution remains the near-term read-through
Initial IM-1021 lymphoma data expected in 2026
Additional clinical and IND milestones across the oncology pipeline

BearKey bullets

IM-1021, IM-1617, IM-3050, and preclinical ADC programs remain dependent on early clinical execution, enrollment, safety, and data quality.
No reliable company-provided consensus comparison or complete post-print estimate-revision series is available; the positive analyst target changes are limited and secondary-source based.
Quarterly losses and continued R&D investment could reduce the stated 2028 runway and eventually create dilution risk.

WatchKey bullets

Varegacestat regulatory review toward PDUFA decision

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Post-earnings T+3

Base case: $31 (p=45%)

Target spread vs base: +45% / -35%

Scenario probabilities

Bull Target: $45 (p=25%)Base Target: $31 (p=45%)Bear Target: $20 (p=30%)

Commentary

The company source is concrete: Immunome’s August 11 SEC 8-K Exhibit 99.1 reported Q2 results, RINGSIDE outcomes, FDA acceptance of the varegacestat NDA, pipeline progress, and runway into 2028. Price action was initially positive but volatile, with gains on August 11-12 followed by a decline on August 13; the latest RankAlpha anchor was $28.52 on August 21. Secondary analyst data show Wedbush and Truist raised targets on August 12 while maintaining positive ratings, but no verified consensus EPS surprise or broader estimate-revision series is available. The deterministic prior remains negative, so this is a milestone-driven monitoring setup rather than a high-conviction long. [#SEC-8K-2026-08-11] https://stockanalysis.com/stocks/imnm/history/

As of 2026-08-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings pipeline execution remains the near-term read-through
Initial IM-1021 lymphoma data expected in 2026
Additional clinical and IND milestones across the oncology pipeline

Scenarios

Bull Target (Scenario probability)

$45 / p=25% prob

Base Target (Scenario probability)

$31 / p=45% prob

Bear Target (Scenario probability)

$20 / p=30% prob

Analysis 2026-08-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.58

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-04-28
Varegacestat regulatory review toward PDUFA decision
The FDA accepted Immunome’s NDA for varegacestat in desmoid tumors and assigned an April 28, 2027 PDUFA target action date. Approval would materially reduce lead-asset risk; delay, rejection, or restrictive labeling would pressure the shares. [#SEC-8K-2026-08-11]
Prob 70.00% • Move 25.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Post-earnings pipeline execution remains the near-term read-through
2026-08-24
The SEC Exhibit 99.1 filed with the August 11 8-K confirmed strong RINGSIDE efficacy, FDA acceptance of the varegacestat NDA, first-patient dosing for IM-1617 and IM-3050, and cash expected to fund operations into 2028. Available price data show a positive initial move after the release but subsequent volatility: shares rose 2.18% on August 11 and 6.63% on August 12, then fell 5.61% on August 13. The packet does not provide a reliable consensus comparison, so this is a milestone read-through rather than a quantified earnings-surprise thesis. [#SEC-8K-2026-08-11] https://stockanalysis.com/stocks/imnm/history/
Prob 65% • Move 4% • Priced-in 80%

Long-term Catalysts

Months to a year

Initial IM-1021 lymphoma data expected in 2026
2026-12-31
The Phase 1 IM-1021 study is ongoing, with objective responses observed at multiple dose levels, and initial lymphoma data are expected in 2026. Early clinical data could validate a second asset, but the dataset and durability remain unproven. [#SEC-8K-2026-08-11]
Prob 55% • Move 20% • Priced-in 35%
Additional clinical and IND milestones across the oncology pipeline
2026-12-31
IM-1617 and IM-3050 have entered Phase 1, while Immunome expects IND submissions for IM-1340 and IM-1335 in mid- and late-2026. These milestones increase pipeline breadth but remain early-stage and safety- and enrollment-dependent. [#SEC-8K-2026-08-11]
Prob 60% • Move 10% • Priced-in 30%

Risks

IM-1021, IM-1617, IM-3050, and preclinical ADC programs remain dependent on early clinical execution, enrollment, safety, and data quality.
No reliable company-provided consensus comparison or complete post-print estimate-revision series is available; the positive analyst target changes are limited and secondary-source based.
Quarterly losses and continued R&D investment could reduce the stated 2028 runway and eventually create dilution risk.
Recent open-market sales by a director and chief business officer may weigh on sentiment, although they do not establish an operating deterioration thesis. [#SEC-FORM4-2026-08-12]
The post-release price reaction was volatile rather than consistently confirming the thesis, with gains on August 11-12 followed by a decline on August 13; available market data do not attribute those moves specifically to earnings. Source: https://stockanalysis.com/stocks/imnm/history/.
Varegacestat may face regulatory delay, non-approval, safety concerns, or restrictive labeling despite positive RINGSIDE results.

Peers

Symbol	Summary
IOVA	Closest provided oncology development-stage benchmark by market capitalization, but its cell-therapy modality and commercial stage differ materially from Immunome’s targeted oncology pipeline.
IRON	Similar market-cap clinical-stage biotech benchmark, though its non-oncology focus limits operating read-through; useful mainly for milestone and financing-risk comparison.
GRAL	Similar market capitalization but a diagnostics business, making it a weak operating peer and unsuitable for direct valuation comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-24

Loading AI feed…

Symbol

Summary

IOVA

Closest provided oncology development-stage benchmark by market capitalization, but its cell-therapy modality and commercial stage differ materially from Immunome’s targeted oncology pipeline.

IRON

Similar market-cap clinical-stage biotech benchmark, though its non-oncology focus limits operating read-through; useful mainly for milestone and financing-risk comparison.

GRAL

Similar market capitalization but a diagnostics business, making it a weak operating peer and unsuitable for direct valuation comparison.